The role of MGMT testing in clinical practice: A report of the association for molecular pathology

Journal of Molecular Diagnostics

Volumn 15, Issue 5, 2013, Pages 539-555

  Cankovic, Milena ^a   Nikiforova, Marina N ^b   Snuderl, Matija ^c   Adesina, Adekunle M ^d   Lindeman, Neal ^e   Wen, Patrick Y ^f,g   Lee, Eudocia Q ^f,g  

^a HENRY FORD HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; BISULFITE; ISOCITRATE DEHYDROGENASE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MOLECULAR MARKER; NITROSOUREA; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHROMOSOME 1P; CLINICAL PRACTICE; CLINICAL TRIAL; CPG ISLAND; GENOME; GLIOBLASTOMA; GLIOMA; HETEROZYGOSITY LOSS; HUMAN; MEDICAL SPECIALIST; METHYLATION; MOLECULAR PATHOLOGY; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PHENOTYPE; PROMOTER REGION; PYROSEQUENCING;

CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; GENETIC TESTING; GLIOMA; HUMANS; PHENOTYPE; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84882255755     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.05.011     Document Type: Article

References (112)

1. T.A. Dolecek, J.M. Propp, N.E. Stroup, and C. Kruchko CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009 Neuro Oncol 14 Suppl 5 2012 v1 v49
2. N. Pouratian, and D. Schiff Management of low-grade glioma Curr Neurol Neurosci Rep 10 2010 224 231
3. F. Pignatti, M. van den Bent, D. Curran, C. Debruyne, R. Sylvester, P. Therasse, D. Afra, P. Cornu, M. Bolla, C. Vecht, A.B.M.F. Karim European Organization for Research and Treatment of Cancer Brain Tumor Cooperative Group; European Organization for Research and Treatment of Cancer Radiotherapy Cooperative Group Prognostic factors for survival in adult patients with cerebral low-grade glioma J Clin Oncol 20 2002 2076 2084
4. P.Y. Wen, and S. Kesari Malignant gliomas in adults [Erratum appeared in N Engl J Med 2008, 359:877] N Engl J Med 359 2008 492 507
5. N. Sanai, and M.S. Berger Recent surgical management of gliomas Adv Exp Med Biol 746 2012 12 25
6. R. Stupp, W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, R.O. Mirimanoff European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
7. T.N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. Mackey, J.A. Butman, K. Camphausen, J. Park, P.S. Albert, and H.A. Fine Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
8. H.S. Friedman, M.D. Prados, P.Y. Wen, T. Mikkelsen, D. Schiff, L.E. Abrey, W.K.A. Yung, N. Paleologos, M.K. Nicholas, R. Jensen, J. Vredenburgh, J. Huang, M. Zheng, and T. Cloughesy Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
9. E.T. Wong, K.R. Hess, M.J. Gleason, K.A. Jaeckle, A.P. Kyritsis, M.D. Prados, V.A. Levin, and W.K.A. Yung Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials J Clin Oncol 17 1999 2572 2578
10. M.J. van den Bent, D. Afra, O. de Witte, M. Ben Hassel, S. Schraub, K. Hoang-Xuan, P.O. Malmström, L. Collette, M. Piérart, R. Mirimanoff, A.B.M.F. Karim EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial [Erratum appeared in Lancet 2006, 367:1818] Lancet 366 9490 2005 985 990
11. W. Wick, C. Hartmann, C. Engel, M. Stoffels, J. Felsberg, F. Stockhammer, M.C. Sabel, S. Koeppen, R. Ketter, R. Meyermann, M. Rapp, C. Meisner, R.D. Kortmann, T. Pietsch, O.D. Wiestler, U. Ernemann, M. Bamberg, G. Reifenberger, A. von Deimling, and M. Weller NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide [Erratum appeared in J Clin Oncol 2010, 28:708] J Clin Oncol 27 2009 5874 5880
12. G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre, M. Mehta, W. Curran Intergroup Radiation therapy Oncology Group Trial 9402 Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation therapy Oncology Group Trial 9402 J Clin Oncol 24 2006 2707 2714
13. M.J. van den Bent, A.F. Carpentier, A.A. Brandes, M. Sanson, M.J.B. Taphoorn, H.J.J.A. Bernsen, M. Freanay, C.C. Tijssen, W. Grisold, L. Sipos, H. Haaxma-Reiche, J.M. Kros, M.C.M. van Kouwenhoven, C.J. Vecht, A. Allgeier, D. Lacombe, and T. Gorlia Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 2006 2715 2722
14. M.J. van Den Bent, K. Hoang-Xuan, A.A. Brandes, J.M. Kros, M.C.M. Kouwenhoven, M.J.B. Taphoorn, J.Y. Delattre, H.J.J.B. Bernsen, M. Frenay, C. Tijssen, W. Grisold, L. Sipos, R.H. Enting, W.N.M. Dinjens, P. French, C.J. Vecht, A. Allgeier, D.A. Lacombe, and T. Gorlia Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors (AOD) J Clin Oncol 30 2012 (Suppl; abstract 2)
15. J.G. Cairncross, M. Wang, E.G. Shaw, R.B. Jenkins, B.W. Scheithauer, D. Brachman, J.C. Buckner, K.L. Fink, L. Souhami, N. Laperriere, W.J. Curran, and M.P. Mehta Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study J Clin Oncol 30 2012 (Suppl; abstract 2008b)
16. C. Hartmann, B. Hentschel, M. Tatagiba, J. Schramm, O. Schnell, C. Seidel, R. Stein, G. Reifenberger, T. Pietsch, A. von Deimling, M. Loeffler, M. Weller German Glioma Network Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17 2011 4588 4599
17. H. Yan, D.W. Parsons, G. Jin, R. McLendon, B.A. Rasheed, W. Yuan, I. Kos, I. Batinic-Haberle, S. Jones, G.J. Riggins, H. Friedman, A. Friedman, D. Reardon, J. Herndon, K.W. Kinzler, V.E. Velculescu, B. Vogelstein, and D.D. Bigner IDH1 and IDH2 mutations in gliomas N Engl J Med 360 2009 765 773
18. H.J. Dubbink, W. Taal, R. van Marion, J.M. Kross, I. van Heuvel, J.E. Bromberg, B.A. Zonnenberg, C.B.L. Zonnenberg, T.J. Postma, J.M.M. Gijtenbeek, W. Boogerd, F.H. Groenendijk, P.A.E.S. Smitt, W.N.M. Dinjens, and M.J. van den Bent IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide Neurology 73 2009 1792 1795
19. C. Houillier, X. Wang, G. Kaloshi, K. Mokhtari, R. Guillevin, J. Laffaire, S. Paris, B. Boisselier, A. Idbaih, F. Laigle-Donadey, K. Hoang-Xuan, M. Sanson, and J.Y. Delattre IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas Neurology 75 2010 1560 1566
20. Y.H. Kim, S. Nobusawa, M. Mittelbronn, W. Paulus, B. Brokinkel, K. Keyvani, U. Sure, K. Wrede, Y. Nakazato, A. Vital, L. Mariani, R. Stawski, T. Watanabe, U. De Girolami, P. Kleihues, and H. Ohgaki Molecular classification of low-grade diffuse gliomas Am J Pathol 177 2010 2708 2714
21. M.J. van den Bent, H.J. Dubbink, Y. Marie, A.A. Brandes, M.J. Taphoorn, P. Wesseling, M. Frenay, C.C. Tijssen, D. Lacombe, A. Idbaih, R. van Marion, J.M. Kros, W.N. Dinjens, T. Gorlia, and M. Sanson IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 2010 1597 1604
22. A. Korshunov, J. Meyer, D. Capper, A. Christians, M. Remke, H. Witt, S. Pfister, A. von Deimling, and C. Hartmann Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma Acta Neuropathol 118 2009 401 405
23. J.G. Cairncross, K. Ueki, M.C. Zlatescu, D.K. Lisle, D.M. Finkelstein, R.R. Hammond, J.S. Silver, P.C. Stark, D.R. Macdonald, Y. Ino, D.A. Ramsay, and D.N. Louis Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas J Natl Cancer Inst 90 1998 1473 1479
24. G.S. Bauman, Y. Ino, K. Ueki, M.C. Zlatescu, B.J. Fisher, D.R. Macdonald, L. Stitt, D.N. Louis, and J.G. Cairncross Allelic loss of chromosome 1 p and radiotherapy plus chemotherapy in patients with oligodendrogliomas Int J Radiat Oncol Biol Phys 48 2000 825 830
25. R.B. Jenkins, H. Blair, K.V. Ballman, C. Giannini, R.M. Arusell, M. Law, H. Flynn, S. Passe, S. Felten, P.D. Brown, E.G. Shaw, and J.C. Buckner A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Res 66 2006 9852 9861
26. C.A. Griffin, P. Burger, L. Morsberger, R. Yonescu, and S. Swierczynski Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss J Neuropathol Exp Neurol 65 2006 988 994
27. M. Snuderl, A.F. Eichler, K.L. Ligon, Q.U. Vu, M. Silver, R.A. Betensky, A.H. Ligon, P.Y. Wen, D.N. Louis, and A.J. Iafrate Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss Clin Cancer Res 15 2009 6430 6437
28. A.L. Wiens, L. Cheng, E.C. Bertsch, K.A. Johnson, S. Zhang, and E.M. Hattab Polysomy of chromosomes 1 and/or 19 is common and associated with less favorable clinical outcome in oligodendrogliomas: fluorescent in situ hybridization analysis of 84 consecutive cases J Neuropathol Exp Neurol 71 2012 618 624
29. Y. Okamoto, P.L. Di Patre, C. Burkhard, S. Horstmann, B. Jourde, M. Fahey, D. Schüler, N.M. Probst-Hensch, M.G. Yasargil, Y. Yonekawa, U.M. Lütolf, P. Kleihues, and H. Ohgaki Population-based study of incidence, survival rates, and genetic alterations of low-grade astrocytomas and oligodendrogliomas Acta Neuropathol 108 2004 49 56
30. C.H. Rickert, R. Sträter, P. Kaatsch, H. Wassermann, H. Jürgens, B. Dockhorn-Dworniczak, and W. Paulus Pediatric high-grade astrocytomas show chromosomal imbalances distinct from adult cases Am J Pathol 158 2001 1525 1532
31. M. Alonso, R. Hamelin, M. Kim, K. Porwancher, T. Sung, P. Oarhar, D.C. Miller, and E.W. Newcomb microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors Cancer Res 61 2001 2124 2128
32. I.F. Pollack, S.D. Finkelstein, J. Burnham, E.J. Holmes, R.L. Hamilton, A.J. Yates, J.L. Finlay, R. Sposto Children's Cancer Group Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort Cancer Res 61 2001 7404 7407
33. A.M. Donson, S.O. Addo-Yobo, M.H. Handler, L. Gore, and N.K. Foreman MGMT promoter methylation Correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma Pediatr Blood Cancer 48 2007 403 407
34. A.T. Natarajan, S. Vermeulen, F. Darroudi, M.B. Valentine, T.P. Brent, S. Mitra, and K. Tano Chromosomal localization of human O6-methylguanine-DNA methyltransferase (MGMT) gene by in situ hybridization Mutagenesis 7 1992 83 85
35. K. Tano, S. Shiota, J. Collier, R.S. Foote, and S. Mitra Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine [Erratum appeared in Proc Natl Acad Sci USA 1990, 87:3253] Proc Natl Acad Sci USA 87 1990 686 690
36. L.C. Harris, P.M. Potter, K. Tano, S. Shiota, S. Mitra, and T.P. Brent Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene Nucleic Acids Res 16 1991 6163 6167
37. L.C. Harris, J.S. Remack, and T.P. Brent Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine-DNA methyltransferase gene Nucleic Acids Res 22 1994 4614 4619
38. G.S. Watts, R.O. Pieper, J.F. Costello, Y.M. Peng, W.S. Dalton, and B.W. Futscher Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene Mol Cell Biol 17 1997 5612 5619
39. X.C. Qian, and T.P. Brent Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene Cancer Res 57 1997 3672 3677
40. R.O. Pieper Understanding and manipulating O6-methylguanine-DNA methyltransferase expression Pharmacol Ther 74 1997 285 297
41. J.F. Costello, B.W. Futscher, K. Tano, D.M. Graunke, and R.O. Pieper Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells J Biol Chem 269 1994 17228 17237
42. J.F. Costello, B.W. Futscher, R.A. Kroes, and R.O. Pieper Methylation-related chromatin structure is associated with exclusion of transcription factors from and suppressed expression of the O-6-methylguanine DNA methyltransferase gene in human glioma cell lines Mol Cell Biol 14 1994 6515 6521
43. R.O. Pieper, S. Patel, S.A. Ting, B.W. Futscher, and J.F. Costello Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene J Biol Chem 271 1996 13916 13924
44. T. Nakagawachi, H. Soejima, T. Urano, W. Zhao, K. Higashimoto, and Y. Satoh Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer Oncogene 22 2003 8835 8844
45. M. Esteller, S.R. Hamilton, P.C. Burger, S.B. Baylin, and J.G. Herman Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 1999 793 797
46. S. Everhard, J. Tost, H. El Abdalaoui, E. Crinière, F. Busato, Y. Marie, I.G. Gut, M. Sanson, K. Mokhtari, F. Laigle-Donadey, K. Hoang-Xuan, J.Y. Delattre, and J. Thillet Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas Neuro Oncol 11 2009 348 356
47. T. Rein, M.L. DePamphilis, and H. Zorbas Identifying 5-methylcytosine and related modifications in DNA genomes Nucleic Acids Res 26 1998 2255 2264
48. M. Esteller, J. Garcia-Foncillas, E. Andion, S.N. Goodman, O.F. Hidalgo, V. Vanaclocha, S.B. Baylin, and J.G. Herman Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [Erratum appeared in N Engl J Med 2000, 343:1740] N Engl J Med 343 2000 1350 1354
49. W.A. Palmisano, K.K. Divine, G. Saccomanno, F.D. Gilliland, S.B. Baylin, J.G. Herman, and S.A. Belinsky Predicting lung cancer by detecting aberrant promoter methylation in sputum Cancer Res 60 2000 5954 5958
50. M. Cankovic, T. Mikkelsen, M.L. Rosenblum, and R.J. Zarbo A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue Lab Invest 87 2007 392 397
51. S. Everhard, G. Kaloshi, E. Crinière, A. Benouaich-Amiel, J. Lejeune, J. Marie, M. Sanson, M. Kujas, K. Mokhtari, K. Hoang-Xuan, J.Y. Delattre, and J. Thiller MGMT methylation: a marker of response to temozolomide in low-grade gliomas Ann Neurol 60 2006 740 743
52. M.E. Hegi, A.C. Diserens, T. Gorlia, M.F. Hamou, N. de Tribolet, M. Weller, J.M. Kros, J.A. Hainfellner, W. Mason, L. Mariani, J.E. Bromberg, P. Hau, R.O. Mirimanoff, J.G. Cairncross, R.C. Janzer, and R. Stupp MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
53. C.A. Eads, K.D. Danenberg, K. Kawakami, L.B. Saltz, C. Blake, D. Shibata, P.V. Danenberg, and P.W. Laird MethyLight: a high-throughput assay to measure DNA methylation Nucleic Acids Res 28 2000 e32
54. S. Ogino, T. Kawasaki, M. Brahmandam, M. Cantor, G.J. Kirkner, D. Spiegelman, G.M. Makrigiorgos, D.J. Weisenberger, P.W. Laird, M. Loda, and C.S. Fuchs Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis J Mol Diagn 8 2006 209 217
55. T. Mikeska, C. Bock, O. El-Maari, A. Hubner, D. Ehentraut, J. Schramm, J. Felsberg, P. Kahl, R. Büttner, T. Pietsch, and A. Waha Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfate restriction analysis J Mol Diagn 9 2007 368 381
56. A. Agah, M. Aghajan, F. Mashayekhi, S. Amini, R.W. Davis, J.D. Plummer, M. Ronaghi, and P.B. Griffin A multi-enzyme model for pyrosequencing Nucleic Acids Res 32 2004 e166
57. J.F. De Groot, E.P. Sulman, and K.D. Aldape Multigene sets for clinical application in glioma J Natl Compr Canc Netw 9 2011 449 457
58. M. Frommer, L.E. McDonald, D.S. Milalr, C.M. Collis, F. Watt, G.W. Grigg, P.L. Molloy, and C.L. Paul A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands Proc Natl Acad Sci USA 89 1992 1827 1831
59. A.L. Brunner, D.S. Johnson, S.W. Kim, A. Valouev, T.E. Reddy, N.F. Neff, E. Anton, C. Medina, L. Nguyen, E. Chiao, C.B. Oyolu, G.P. Schroth, D.M. Absher, J.C. Baker, and R.M. Myers Distinct DNA methylation patterns characterize differentiated human embryonic stem cells and developing human fetal liver Genome Res 19 2009 1044 1056
60. A. Meissner, A. Gnirke, G.W. Bell, B. Ramsahoye, E.S. Lander, and R. Jaenisch Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis Nucleic Acids Res 33 2005 5868 5877
61. G. Wu, N. Yi, D. Absher, and D. Zhi Statistical quantification of methylation levels by next-generation sequencing PLoS One 6 2011 e21034
62. J.P. Schouten, C.J. McElgunn, R. Waaijer, D. Zwijnenburg, F. Diepvens, and G. Pals Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification Nucleic Acids Res 30 2002 e57
63. A.O.H. Nygren, N. Ameziane, H.M.B. Duarte, R.N.C.P. Vijzelaar, Q. Waisfisz, C.J. Hess, J.P. Schouten, and A. Errami Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences Nucleic Acids Res 33 2005 e128
64. J.W.M. Jeuken, S.J.B. Cornelissen, M. Vriezen, M.M.G. Dekkers, A. Errami, A. Sijben, S.H.E. Boots-Sprenger, and P. Vesseling MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas Lab Invest 87 2007 1055 1065
65. J.A. Maxwell, S.P. Johnson, J.A. Quinn, R.E. McLendon, F. Ali-Osman, A.H. Friedman, J.E. Herndon 2nd, K. Bierau, J. Bigley, D.D. Bigner, and H.S. Friedman Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma Mol Cancer Ther 5 2006 2531 2539
66. M. Möllemann, M. Wolter, J. Felsberg, V.P. Collins, and G. Reifenberger Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors Int J Cancer 113 2005 379 385
67. M. Brell, A. Tor tosa, E. Verger, J.M. Gil, N. Viñolas, S. Villá, J.J. Acebes, L. Caral, T. Pujol, I. Ferrer, T. Ribalta, and F. Graus Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas Clin Cancer Res 11 2005 5167 5174
68. E.M. Grasbon-Frodl, F.W. Kreth, M. Ruiter, O. Schnell, K. Bise, J. Felsberg, G. Reifenberger, J.C. Tonn, and H.A. Kretzschmar Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas Int J Cancer 121 2007 2458 2464
69. A.B. Håvik, P. Brandal, H. Honne, H.S. Dahlback, D. Scheie, M. Hektoen, T.R. Meling, E. Helseth, S. Heim, R.A. Lothe, and G.E. Lind MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR J Transl Med 10 2012 36 49
70. J. Dunn, A. Baborie, F. Alam, K. Joyce, M. Moxham, R. Sibson, D. Crooks, D. Husband, A. Shenoy, A. Brodbelt, H. Wong, T. Liloglou, B. Haylock, and C. Walker Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy Br J Cancer 101 2009 124 131
71. A.R. Sepulveda, D. Jones, S. Ogino, W. Samowitz, M.L. Gulley, R. Edwards, V. Levenson, V.M. Pratt, B. Yang, K. Nafa, L. Yan, and P. Vitazka CpG methylation analysis-current status of clinical assays and potential applications in molecular diagnostics J Mol Diagn 11 2009 266 2278
72. W. Zhao, H. Soejima, K. Higashimoto, T.T. Nagawachi, T.T. Urano, S.S. Kudo, S.S. Matsukura, S.S. Matsuo, K.K. Joh, and T.T. Mukai The essential role of histone H3 Lys9 di-methylation and MeCP2 binding in MGMT silencing with poor DNA methylation of the promoter CpG island J Biochem 137 2005 431 440
73. N. Shah, B. Lin, Z. Sibenaller, T. Ryken, H. Lee, J.G. Yoon, S. Rostad, and G. Foltz Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM PLoS One 6 2011 e16146
74. M.E. Hegi, A.C. Diserens, S. Godard, P.Y. Dietrich, L. Regli, S. Ostermann, P. Otten, G. Van Melle, N. de Tribolet, and R. Stupp Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 2004 1871 1874
75. I. Vlassenbroeck, S. Califice, A.C. Diserens, E. Migliavacca, J. Straub, I. Di Stefano, F. Moreau, M.F. Hamou, I. Renard, M. Delorenzi, B. Flamion, J. DiGuiseppi, K. Bierau, and M.E. Hegi Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma J Mol Diagn 10 2008 332 337
76. L. Karayan-Tapon, V. Quillien, J. Guilhot, M. Wager, G. Fromant, S. Saikali, A. Etcheverry, A. Hamlat, D. Loussouarn, L. Campion, M. Campone, F.M. Vallette, and C. Gratas-Rabbia-Ré Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods J Neurooncol 97 2010 311 322
77. A. Christians, C. Hartmann, A. Benner, J. Meyer, A. von Deimling, M. Weller, W. Wick, and M. Weiler Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma PLoS One 7 2012 e33449
78. M. Uno, S.M. Oba-Shinjo, A.A. Camargo, R.P. Moura, P.H. de Aguiar, H.N. Cabrera, M. Begnami, S. Rosemberg, M.J. Teixeira, and S.K.N. Marie Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma Clinics 66 2011 1747 1755
79. D.S. Malley, R.A. Hamoudi, S. Kocialkowski, D.M. Pearson, V.P. Collins, and K. Ichimura A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts Acta Neuropathol 121 2011 651 661
80. D. Sciuscio, A.C. Diserens, K. van Dommelen, D. Martinet, G. Jones, R.C. Janzer, C. Pollo, M.F. Hamou, B. Kaina, R. Stupp, M. Levivier, and M.E. Hegi Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres Clin Cancer Res 17 2011 255 266
81. M. Toyota, N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin, and J.P. Issa CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci USA 96 1999 8681 8686
82. D.J. Weisenberger, K.D. Siegmund, M. Campan, J. Young, T.I. Long, M.A. Faasse, G.H. Kang, M. Widschwendter, D. Weener, D. Buchanan, H. Koh, L. Simms, M. Barker, B. Leggett, J. Levine, M. Kim, A.J. French, S.N. Thibodeau, J. Jass, R. Haile, and P.W. Laird CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat Genet 38 2006 787 793
83. H. Noushmehr, D.J. Weisenberger, K. Diefes, H.S. Phillips, K. Pujara, B.P. Berman, F. Pan, C.E. Pelloski, E.P. Sulman, K.P. Bhat, R.G. Verhaak, K.A. Hoadley, D.N. Hayes, C.M. Perou, H.K. Schmidt, L. Ding, R.K. Wilson, D. Van Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L.M. Cope, J. Buckley, J.G. Herman, S.B. Baylin, P.W. Laird, K. Aldape Cancer Genome Atlas Research Network Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma Cancer Cell 17 2010 510 522
84. K. Kawakami, A. Matsunoki, M. Kaneko, K. Saito, G. Watanabe, and T. Minamoto Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer Cancer Sci 102 2011 166 174
85. S. Ogino, K. Nosho, G.J. Kirkner, T. Kawasaki, A.T. Chan, E.S. Schernhammer, E.L. Giovannucci, and C.S. Fuchs A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer J Natl Cancer Inst 100 2008 1734 1738
86. F. Ohka, A. Natsume, K. Motomura, Y. Kishida, Y. Kondo, T. Abe, Y. Nakasu, H. Namba, K. Wakai, T. Fukui, H. Momota, K. Iwami, S. Kinjo, M. Ito, M. Fujii, and T. Wakabayashi The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter Methylation and is a better prognostic factor for glioma PLoS One 6 2011 e23332
87. M.R. Gilbert, M. Wang, K.D. Aldape, R. Stupp, M. Hegi, K.A. Jaeckle, T.S. Armstrong, J.S. Wefel, M. Won, D.T. Blumenthal, A. Mahajan, C.J. Schultz, S.C. Erridge, P.D. Brown, A. Chakravarti, W.J. Curran Jr., and M.P. Mehta RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM) Neuro Oncol 13 Suppl 3 2011 iii51 (Abstract NO-46)
88. R. Stupp, M.E. Hegi, W.P. Mason, M.J. van den Bent, M.J. Taphoorn, R.C. Janzer, S.K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A.A. Brandes, J. Gijtenbeek, C. Marosi, C.J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J.G. Cairncross, R.O. Mirimanoff European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
89. A.A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession, G. Tallini, R. Bertorelle, S. Bartolini, F. Calbucci, A. Andreoli, G. Frezza, M. Leonardi, F. Spagnolli, and M. Ermani MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2008 2192 2197
90. M. Weller, R. Stupp, G. Reifenberger, A.A. Brandes, M.J. van den Bent, W. Wick, and M.E. Hegi MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 2010 39 51
91. A.A. Brandes, A. Tosoni, G. Cavallo, R. Bertorelle, V. Gioia, E. Franceschi, M. Biscuola, V. Blatt, L. Crinò, and M. Ermani Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo Italiano cooperative di neuro-oncologia (GICNO) Br J Cancer 95 2006 115 1160
92. D.P. Cahill, P.J. Codd, T.T. Batchelor, W.T. Curry, and D.N. Louis MSH6 inactivation and emergent temozolomide resistance in human glioblastomas Clin Neurosurg 55 2008 165 171
93. D.P. Cahill, K.K. Levine, R.A. Betensky, P.J. Codd, C.A. Romany, L.B. Reavie, T.T. Batchelor, P.A. Futreal, M.R. Stratton, W.T. Curry, A.J. Iafrate, and D.N. Louis Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment Clin Cancer Res 13 2007 2038 2045
94. S. Yip, J. Miao, D.P. Cahill, A.J. Iafrate, K.D. Aldape, C.L. Nutt, and D.N. Louis MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance Clin Cancer Res 15 2009 4622 4629
95. J. Gállego Pérez-Larraya, F. Ducray, O. Chinot, I. Catry-Thomas, L. Taillandier, J.S. Guillamo, C. Campello, A. Monjour, S. Cartalat-Carel, M. Barrie, A. Huchet, P. Beauchesne, M. Matta, K. Mokhtari, M.L. Tanguy, J. Honnorat, and J.Y. Delattre Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial J Clin Oncol 29 2011 3050 3055
96. W. Wick, M. Platten, C. Meisner, J. Felsberg, G. Tabatabai, M. Simon, G. Nikkhah, K. Papsdorf, J.P. Steinbach, M. Sabel, S.E. Combs, J. Vesper, C. Braun, J. Meixensberger, R. Ketter, R. Mayer-Steinacker, G. Reifenberger, M. Weller NOA-08 study Group of Neuro-oncolgy Working Group (NOA) of German Cancer Society Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Lancet Oncol 13 2012 707 715
97. M.J. van den Bent, H.J. Dubbink, M. Sanson, C.R. van der Lee-Haarloo, M. Hegi, J.W. Jeuken, A. Ibdaih, A.A. Brandes, M.J. Taphoorn, M. Frenay, D. Lacombe, T. Gorlia, W.N. Dinjens, and J.M. Kros MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 2009 5881 5886
98. C. Komine, T. Watanabe, Y. Katayama, A. Yoshino, T. Yokoyama, and T. Fukushima Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low grade diffuse astrocytomas Brain Pathol 13 2003 176 184
99. S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E.A. Nacklin, A. Muzikansky, S. Santagata, K.L. Ligon, A.D. Norden, A. Ciampa, J. Bradshaw, B. Levy, G. Radakovic, N. Ramakrishna, P.M. Black, and P.Y. Wem Phase II study of protracted daily temozolomide for low-grade gliomas in adults Clin Cancer Res 15 2009 330 337
100. N. Levin, I. Lavon, B. Zelikovitsh, D. Fuchs, F. Bokstein, Y. Fellig, and T. Siegal Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression Cancer 106 2006 1759 1765
101. A. Tosoni, E. Franceschi, M. Ermani, R. Bertorelle, L. Bonaldi, V. Blatt, and A.A. Brandes Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas J Neurooncol 89 2008 179 185
102. I.F. Pollack, R.L. Hamilton, R.W. Sobol, J. Burnham, A.J. Yates, E.J. Holmes, T. Zhou, and J.L. Finlay O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 cohort J Clin Oncol 24 2006 3431 3437
103. K.J. Cohen, I.F. Pollack, T. Zhou, A. Buxton, E.J. Holmes, P.C. Burger, D.J. Brat, M.K. Rosenblum, R.L. Hamilton, R.S. Lavey, and R.L. Heideman Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group Neuro Oncol 13 2011 317 323
104. S. Schlosser, S. Wagner, J. Mühlisch, M. Hasselblatt, J. Gerss, J.E.A. Wolff, and M.C. Frühwald MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience Pediatr Blood Cancer 54 2010 228 237
105. J.Y. Lee, C.K. Park, S.H. Park, K.C. Wang, B.K. Cho, and S.K. Kim MGMT promoter gene methylation in pediatric glioblastoma: analysis using MS-MLPA Childs Nerv Syst 27 2011 1877 1883
106. H.S. Friedman, J. Pluda, J.A. Quinn, R.B. Ewesuedo, L. Long, A.H. Friedman, I. Cokgor, O.M. Colvin, M.M. Haglund, D.M. Ashley, J.N. Rich, J. Sampson, A.E. Pegg, R.C. Moschel, R.E. McLendon, J.M. Provenzale, E.S. Stewart, S. Tourt-Uhlig, A.M. Garcia-Turner, J.E. Herndon 2nd, D.D. Bigner, and M.E. Dolan Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma J Clin Oncol 18 2000 3522 3528
107. J.A. Quinn, J. Pluda, M.E. Dolan, S. Delaney, R. Kaplan, J.N. Rich, A.H. Friedman, D.A. Reardon, J.H. Sampson, O.M. Colvin, M.M. Haglund, A.E. Pegg, R.C. Moschel, R.E. McLendon, J.M. Provenzale, S. Gururangan, S. Tourt-Uhlig, J.E. Herndon 2nd, D.D. Bigner, and H.S. Friedman Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma J Clin Oncol 20 2002 2277 2283
108. S.C. Schold Jr., D.M. Kokkinakis, S.M. Chang, M.S. Berger, K.R. Hess, D. Schiff, H.I. Robins, M.P. Mehta, K.L. Fink, R.L. Davis, and M.D. Prados O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas Neuro Oncol 6 2004 28 32
109. A.W. Tolcher, S.L. Gerson, L. Denis, C. Geyer, L.A. Hammond, A. Patnaik,
110. V. Ganière, G. Christen, F. Bally, L. Guillou, A. Pica, S. de Ribaupierre, and R. Stupp Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide Nat Clin Pract 3 2006 339 343
111. R. Stupp, P.Y. Dietrich, S.O. Kraljevic, A. Pica, I. Maillard, P. Maeder, R. Meuli, R. Janzer, G. Pizzolato, R. Miralbell, F. Porchet, L. Regli, N. de Tribolet, R.O. Mirimanoff, and S. Leyvraz Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 2002 1375 1382
112. Y.B. Su, S. Sohn, S.E. Krown, P.O. Livingston, J.D. Wolchok, C. Quinn, L. Williams, T. Foster, K.A. Sepkowitz, and P.B. Chapman Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications [Erratum appeared in J Clin Oncol 2004, 22:2038] J Clin Oncol 22 2004 610 616